VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Frequently asked questions
What sector does VYNE Therapeutics Inc (VYNE) operate in?
VYNE Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is VYNE Therapeutics Inc (VYNE) current stock price?
As of the latest data, VYNE Therapeutics Inc stock price is $28.56, with a previous close of $28.56.
What is VYNE Therapeutics Inc (VYNE) current market capitalization?
VYNE Therapeutics Inc market cap is approximately 19.07 million.
What is VYNE Therapeutics Inc (VYNE) Earnings Per Share (EPS)?
The trailing EPS is -$27.58, and the forward EPS is -$82.50.
What is VYNE Therapeutics Inc (VYNE) EBITDA?
VYNE Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -29.75 million.
Does VYNE Therapeutics Inc (VYNE) pay dividends?
No. VYNE Therapeutics Inc does not pay a dividend.
What is VYNE Therapeutics Inc (VYNE) beta (volatility) score?
VYNE Therapeutics Inc has a beta of 2.006, indicating very high volatility compared to the market.
